Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells

Proteasome inhibitors are emerging as a new class of cancer therapeutics, and bortezomib has shown promise in the treatment of multiple myeloma and mantle cell lymphoma. However, bortezomib has failed to have an effect in preclinical models of glioma. NPI-0052 is a new generation of proteasome inhib...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Vlashi, Erina, Mattes, Malcom, Lagadec, Chann, Donna, Lorenza Della, Phillips, Tiffany M, Nikolay, Polin, McBride, William H, Pajonk, Frank
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Neoplasia Press Inc. 2010
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2822455/
https://ncbi.nlm.nih.gov/pubmed/20165695
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller